Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Bone Therapeutics receives manufacturing authorisation to produce allogeneic bone cell therapy products

Bone Therapeutics : 26 March, 2013  (Company News)
Bone Therapeutics receives both 'Tissue Establishment' and 'GMP' Accreditation for the manufacturing of the company's ALLOB allogeneic bone cell therapy product, being initially developed for the treatment of impaired fractures.


The Tissue Establishment (Intermediate Structure) Accreditation is a pre-requisite for the manufacture of allogeneic cell therapies, and will permit Bone Therapeutics to have enhanced control over the ALLOB production line. Bone Therapeutics' Intermediate Structure will be able to process, preserve, store and distribute human tissues upon their release from LTCG,  the Tissue Bank. Bone Therapeutics will work in collaboration with the LTCG, the accredited Tissue Bank from the CHU Sart-Tilman based in Liege, Belgium and headed up by Prof Yves Beguin.



This approval further strengthens Bone Therapeutics' cell product manufacturing capabilities.  In addition to the allogeneic platform, Bone Therapeutics has autologous 'Production Establishment Accreditation' and manufacturing authorisations, which enables the company to work on PREOB, its autologous bone cell product, and manage all product design, engineering, validation, production and quality assurance to the highest GMP standards.



Enrico Bastianelli, Chief Executive Officer of Bone Therapeutics, commented: "Being awarded with ALLOB manufacturing authorization is great news for Bone Therapeutics.  This recent accreditation follows an earlier Manufacturing Authorization for our lead product, PREOB and we are delighted that we have the necessary approvals to enable the onward development of both products."


Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo